argenx SEARGX -0.17%80 Market Cap is $55,420 Mil as of Jun. 29, 2026. GuruFocus rates ARGX with a GF Score™ of 80/100 and a GF Value™ of $1,363.68 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 1,428 Biotechnology companies, argenx SE ranks better than 99.72% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). argenx SE's share price for the quarter that ended in Mar. 2026 was $730.25. argenx SE's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 62 Mil. Therefore, argenx SE's market cap for the quarter that ended in Mar. 2026 was $45,413 Mil.
argenx SE's quarterly market cap
increased
from Sep. 2025 ($45,411 Mil) to Dec. 2025 ($52,041 Mil) but then
declined
from Dec. 2025 ($52,041 Mil) to Mar. 2026 ($45,413 Mil).
argenx SE's annual market cap
increased
from Dec. 2023 ($22,519 Mil) to Dec. 2024 ($37,368 Mil) and
increased
from Dec. 2024 ($37,368 Mil) to Dec. 2025 ($52,041 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. argenx SE's Enterprise Value for Today is $51,027 Mil.
argenx SE (NAS:ARGX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
argenx SE Market Cap Related Terms
argenx SE Market Cap Historical Data
* Premium members only.
The historical data trend for argenx SE's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, argenx SE's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
argenx SE Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, argenx SE's Market Cap distribution charts can be found below:
* The bar in red indicates where argenx SE's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
argenx SE's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
argenx SE (ARGX) has a Market Cap of $55,420 Mil as of Jun. 29, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on argenx SE and its competitors. According to the industry distribution chart, argenx SE ranks #4 out of 1428 companies in the Biotechnology industry, placing it in the top 0.3%.
Is argenx SE's Market Cap too high?
argenx SE's current Market Cap is $55,420 Mil. The Biotechnology industry median Market Cap is 114.03. argenx SE's value of $55,420 Mil is 48500.4% above this industry median. Based on the distribution chart, argenx SE ranks #4 out of 1428 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, argenx SE has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does argenx SE's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, argenx SE ranks #4 out of 1428 companies for Market Cap. This places argenx SE in the top 0% of its industry — outperforming the majority of peers. The industry median Market Cap is 114.03. argenx SE's value of $55,420 Mil is 48500.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 114.03, based on 1,428 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. argenx SE's current Market Cap of $55,420 Mil is 48500.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on argenx SE and its competitors. For the Biotechnology industry, the median Market Cap is 114.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. argenx SE's current Market Cap is $55,420 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is argenx SE stock overvalued right now?
Based on GuruFocus' analysis, argenx SE (ARGX) is currently considered Significantly Undervalued. The stock's GF Value™ is $1,363.68, compared to a current price of $885.80 — trading 35% below its estimated fair value. The current Market Cap is $55,420 Mil and 48500.4% above the Biotechnology industry median of 114.03. argenx SE's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For argenx SE (ARGX), the current Market Cap is $55,420 Mil as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is argenx SE (ARGX) Overvalued in 2026?
Based on GuruFocus' analysis, argenx SE stock appears to be undervalued.
The current stock price of $885.80 is trading 35% below its estimated GF Value™ of $1,363.68.
GuruFocus considers argenx SE to be Significantly Undervalued.
Key valuation signals for ARGX:
Market Cap: $55,420 Mil
GF Value™: $1,363.68 vs. price of $885.80 (35% below fair value)
Industry Position: 48500.4% above the Biotechnology median (#4 of 1428)
No single metric tells the full story. See the ARGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
80GF Score
Get the complete analysis for ARGX
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARGX has been successfully added to your 
